TITLE

Positive In Vivo Selection of the HIV-1 Envelope Protein gp120 Occurs at Surface-Exposed Regions

AUTHOR(S)
Joos, Beda; Fischer, Marek; Schweizer, Andreas; Kuster, Herbert; Böni, Jürg; Wong, Joseph K.; Weber, Rainer; Trkola, Alexandra; Günthard, Huldrych F.
PUB. DATE
July 2007
SOURCE
Journal of Infectious Diseases;7/15/2007, Vol. 196 Issue 2, p313
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The rapid evolution of human immunodeficiency virus (HIV) envelope represents a major challenge to vaccine and drug development, particularly because the underlying mechanisms are not completely understood. To explore whether distinct patterns of positive selection within the envelope glycoprotein (gp) 120 exist and are associated with functionally relevant domains, we conducted a long-term survey of sequence evolution in 20 HIV-1-infected persons who interrupted antiretroviral therapy. In total, 1753 clonal sequences encompassing the C2-V3-C3 region of gp120 were derived. Strikingly, positively selected amino acids mapped almost exclusively (P = .0003) to externally accessible residues on the gp120 crystal structure. The current understanding of envelope structure and function associates the main determinants of viral entry and the targets for neutralizing antibodies with these exterior regions of gp120, strongly suggesting that the observed adaptive evolution of these sites occurs in response to respective selective forces.
ACCESSION #
25812371

 

Related Articles

  • B Cell Repertoire Analysis Identifies New Antigenic Domains on Glycoprotein B of Human Cytomegalovirus which Are Target of Neutralizing Antibodies. Pötzsch, Sonja; Spindler, Nadja; Wiegers, Anna-Katharina; Fisch, Tanja; Rücker, Pia; Sticht, Heinrich; Grieb, Nina; Baroti, Tina; Weisel, Florian; Stamminger, Thomas; Martin-Parras, Luis; Mach, Michael; Winkler, Thomas H. // PLoS Pathogens;Aug2011, Vol. 7 Issue 8, Special section p1 

    Human cytomegalovirus (HCMV), a herpesvirus, is a ubiquitously distributed pathogen that causes severe disease in immunosuppressed patients and infected newborns. Efforts are underway to prepare effective subunit vaccines and therapies including antiviral antibodies. However, current vaccine...

  • The Antiviral Efficacy of HIV-Specific CD8+ T-Cells to a Conserved Epitope Is Heavily Dependent on the Infecting HIV-1 Isolate. Ranasinghe, Srinika R. F.; Kramer, Holger B.; Wright, Cynthia; Kessler, Benedikt M.; di Gleria, Katalin; Zhang, Yonghong; Gillespie, Geraldine M.; Blais, Marie-Eve; Culshaw, Abigail; Pichulik, Tica; Simmons, Alison; Rowland-Jones, Sarah L.; McMichael, Andrew J.; Dong, Tao // PLoS Pathogens;May2011, Vol. 7 Issue 5, Special section p1 

    A major challenge to developing a successful HIV vaccine is the vast diversity of viral sequences, yet it is generally assumed that an epitope conserved between different strains will be recognised by responding T-cells. We examined whether an invariant HLA-B8 restricted Nef90-97 epitope FL8...

  • Design and tests of an HIV vaccine. McMichael, Andrew; Mwau, Matilu; Hanke, Tomas // British Medical Bulletin;Jul2002, Vol. 62 Issue 1, p87 

    It is likely that a successful vaccine against HIV will need to stimulate the innate immune system, generate high levels of neutralising antibody, strong cellular immune responses, and mucosal immunity. Early efforts to develop HIV vaccines attempted to use the virus glycoprotein, gp120, to...

  • Multi-Functional Anti-HIV Agents Based on Amino Acid Sequences Present in Serpin C-Terminal Peptides. Congote, L. F. // Anti-Infective Agents in Medicinal Chemistry;2008, Vol. 7 Issue 2, p126 

    The observation that proteinases located at the surface of HIV-1 target cells were involved in viral infection led to the discovery of the anti-HIV-1 properties of serpin A1(α1-proteinase inhibitor, α1-antitrypsin). Antiviral activity could be explained by the capacity of serpin A1 to...

  • Structure-based design and functional studies of novel noroviral 3C protease chimaeras offer insights into substrate specificity. Herod, Morgan R.; Prince, Cynthia A.; Skilton, Rachel J.; Ward, Vernon K.; Cooper, Jonathan B.; Clarke, Ian N. // Biochemical Journal;12/15/2014, Vol. 464 Issue 3, p461 

    The norovirus NS6 protease is a key target for anti-viral drug development. Noroviruses encode a 2200 amino acid polyprotein which is cleaved by this critical protease at five defined boundary substrates into six mature non-structural (NS) proteins. Studies of the human norovirus (HNV) NS6...

  • New Antiviral Strategy Has Potential Role In HIV Prophylaxis. Kingman, Sharon // BioWorld Today;11/12/2013, Vol. 24 Issue 218, p1 

    The article focuses on the development of an antiviral strategy which seeks to solve the mystery of HIV cell infection. A study was conducted by a team of researchers led by molecular virology professor Greg Towers where they manipulated the interaction between the virus and the host cell to...

  • HIV-1 Adenoviral Vector Vaccines Expressing Multi-Trimeric BAFF and 4-1BBL Enhance T Cell Mediated Anti-Viral Immunity. Kanagavelu, Saravana; Termini, James M.; Gupta, Sachin; Raffa, Francesca N.; Fuller, Katherine A.; Rivas, Yaelis; Philip, Sakhi; Kornbluth, Richard S.; Stone, Geoffrey W. // PLoS ONE;Feb2014, Vol. 9 Issue 2, p1 

    Adenoviral vectored vaccines have shown considerable promise but could be improved by molecular adjuvants. Ligands in the TNF superfamily (TNFSF) are potential adjuvants for adenoviral vector (Ad5) vaccines based on their central role in adaptive immunity. Many TNFSF ligands require aggregation...

  • Soluble HIV-1 Envelope Immunogens Derived from an Elite Neutralizer Elicit Cross-Reactive V1V2 Antibodies and Low Potency Neutralizing Antibodies. Carbonetti, Sara; Oliver, Brian G.; Glenn, Jolene; Stamatatos, Leonidas; Sather, D. Noah // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    We evaluated four gp140 Envelope protein vaccine immunogens that were derived from an elite neutralizer, subject VC10042, whose plasma was able to potently neutralize a wide array of genetically distinct HIV-1 isolates. We sought to determine whether soluble Envelope proteins derived from the...

  • Inhibition of Membrane Fusion as a Target for Antiviral Therapy. Plemper, Richard K.; Hammond, Anthea L. // Anti-Infective Agents in Medicinal Chemistry;2007, Vol. 6 Issue 4, p248 

    Entry of enveloped viruses into cells is initiated by virus binding to a target cell receptor. Subsequent conformational changes in the viral envelope proteins are triggered either by receptor binding or by the low pH of the endosome, depending on the virus family, and facilitate fusion, or...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics